A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Veerle Bossuyt¹, Elena Provenzano², W Fraser Symmans³, Fleur Webster⁴, Kimberly H Allison⁵, Chau Dang⁶, Helenice Gobbi⁷, Janina Kulka⁸, Sunil R Lakhani⁹, Takuya Moriya¹⁰, Cecily M Quinn^{11

12}, Anna Sapino¹³, Stuart Schnitt¹⁴, D Mark Sibbering¹⁵, Elzbieta Slodkowska¹⁶, Wentao Yang¹⁷, Puay Hoon Tan¹⁸, Ian Ellis¹⁹

Affiliations

¹ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Department of Histopathology, Addenbrookes Hospital, Cambridge, UK.
³ Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ International Collaboration on Cancer Reporting, Surry Hills, NSW, Australia.
⁵ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
⁶ Memorial Sloan Kettering Cancer Center, West Harrison, NY, USA.
⁷ Department of Surgical Clinic, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.
⁸ Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.
⁹ Centre for Clinical Research, and Pathology Queensland, University of Queensland, Brisbane, Qld, Australia.
¹⁰ Department of Pathology, Kawasaki Medical School, Okayama, Japan.
¹¹ Department of Histopathology, St Vincent's University Hospital, Dublin, Ireland.
¹² School of Medicine, University College, Dublin, Ireland.
¹³ Department of Medical Sciences, University of Turin, Turin, Italy.
¹⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
¹⁵ University Hospitals of Derby and Burton NHS Trust, Royal Derby Hospital, Derby, UK.
¹⁶ Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
¹⁷ Shanghai Cancer Center, Shanghai, China.
¹⁸ Luma Medical Centre, Royal Square, Singapore.
¹⁹ Department of Histopathology, Nottingham City Hospital, London, UK.

PMID: 38443320
DOI: 10.1111/his.15165

A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Veerle Bossuyt et al. Histopathology. 2024 Jun.

. 2024 Jun;84(7):1111-1129.

doi: 10.1111/his.15165. Epub 2024 Mar 5.

Authors

Affiliations

¹ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Department of Histopathology, Addenbrookes Hospital, Cambridge, UK.
³ Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ International Collaboration on Cancer Reporting, Surry Hills, NSW, Australia.
⁵ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
⁶ Memorial Sloan Kettering Cancer Center, West Harrison, NY, USA.
⁷ Department of Surgical Clinic, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.
⁸ Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.
⁹ Centre for Clinical Research, and Pathology Queensland, University of Queensland, Brisbane, Qld, Australia.
¹⁰ Department of Pathology, Kawasaki Medical School, Okayama, Japan.
¹¹ Department of Histopathology, St Vincent's University Hospital, Dublin, Ireland.
¹² School of Medicine, University College, Dublin, Ireland.
¹³ Department of Medical Sciences, University of Turin, Turin, Italy.
¹⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
¹⁵ University Hospitals of Derby and Burton NHS Trust, Royal Derby Hospital, Derby, UK.
¹⁶ Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
¹⁷ Shanghai Cancer Center, Shanghai, China.
¹⁸ Luma Medical Centre, Royal Square, Singapore.
¹⁹ Department of Histopathology, Nottingham City Hospital, London, UK.

PMID: 38443320
DOI: 10.1111/his.15165

Abstract

Aims: The International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter-)national pathology and cancer organisations, is an initiative aimed at providing a unified international approach to reporting cancer. ICCR recently published new data sets for the reporting of invasive breast carcinoma, surgically removed lymph nodes for breast tumours and ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions. The data set in this paper addresses the neoadjuvant setting. The aim is to promote high-quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment that can be used for subsequent management decisions for each patient.

Methods: The ICCR convened expert panels of breast pathologists with a representative surgeon and oncologist to critically review and discuss current evidence. Feedback from the international public consultation was critical in the development of this data set.

Results: The expert panel concluded that a dedicated data set was required for reporting of breast specimens post-neoadjuvant therapy with inclusion of data elements specific to the neoadjuvant setting as core or non-core elements. This data set proposes a practical approach for handling and reporting breast resection specimens following neoadjuvant therapy. The comments for each data element clarify terminology, discuss available evidence and highlight areas with limited evidence that need further study. This data set overlaps with, and should be used in conjunction with, the data sets for the reporting of invasive breast carcinoma and surgically removed lymph nodes from patients with breast tumours, as appropriate. Key issues specific to the neoadjuvant setting are included in this paper. The entire data set is freely available on the ICCR website.

Conclusions: High-quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment are critical for subsequent management decisions for each patient.

Keywords: ICCR guidelines; check‐list; data set; invasive carcinoma of the breast; neoadjuvant therapy; protocol; structured report; synoptic report.

PubMed Disclaimer

References

1. Yau C, Osdoit M, van der Noordaa M et al. Residual cancer burden after neoadjuvant chemotherapy and long‐term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022; 23; 149–160.
1. von Minckwitz G, Huang CS, Mano MS et al. Trastuzumab emtansine for residual invasive HER2‐positive breast cancer. N. Engl. J. Med. 2019; 380; 617–628.
1. Masuda N, Lee SJ, Ohtani S et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. 2017; 376; 2147–2159.
1. Bossuyt V, Provenzano E, Symmans WF et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG‐NABCG collaboration. Ann. Oncol. 2015; 26; 1280–1291.
1. Provenzano E, Bossuyt V, Viale G et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an International Working Group. Mod. Pathol. 2015; 28; 1185–1201.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Affiliations

A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Authors

Affiliations

Abstract

References

MeSH terms

LinkOut - more resources

Full Text Sources

Medical